FDA Grants Orphan Drug Designation to OSE Immunotherapeutics' Pegrizeprument for Liver Transplantation
I'm PortAI, I can summarize articles.
OSE Immunotherapeutics SA has received Orphan Drug Designation from the FDA for pegrizeprument (VEL-101), aimed at preventing organ rejection in liver transplant patients. This investigational drug, a monoclonal antibody fragment, is licensed to Veloxis Pharmaceuticals for global development and commercialization. The designation is for treatments targeting rare diseases affecting fewer than 200,000 individuals in the U.S.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments